Evaluation of the efficacy of XELOX for Japanese patients with completely resected stage II / stage III rectal cancer
Phase 2
- Conditions
- Rectal cancer
- Registration Number
- JPRN-UMIN000008634
- Lead Sponsor
- Multicenter Clinical Study Group of Osaka, Colorectal Cancer Treatment Group
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 107
Inclusion Criteria
Not provided
Exclusion Criteria
1) Postoperative complications 2) Active double cancer 3) Severe neuropathy or sensory dysfunction. 4) Women who are pregnant or breast-feeding 5) Serious drug allergy 6) Clinically significant infectious disease 7) Clinically significant psychological disease 8) Patient who has any of the following complications i) Uncontrolled diabetes mellitus ii) Uncontrolled hypertension iii) Interstitial pneumonitis,lung fibrosis iv) Ileus or bowel obstruction v) Clinically significant heart disease 9) Other reasons for being unfit for the study as determined by the attending physician
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 3-year disease free survival rate
- Secondary Outcome Measures
Name Time Method 5-year overall survival rate safety, completion rate, relative dose intensity